Modulating effect of apolipoprotein E polymorphisms on secondary brain insult and outcome after childhood brain

T Y M Lo1, P A Jones, I R Chambers

  • 1Section of Child Life & Health, University of Edinburgh, 20 Sylvan Place, Edinburgh, EH 9 1LF, UK. mils.lo@doctors.org.uk

Insights

Apolipoprotein E (APO E) alleles influence outcomes in children with brain trauma. APO E e4 carriers experienced less cerebral perfusion pressure (CPP) insult, while e3 homozygotes showed good recovery despite significant CPP insult.

Area of Science:

  • Neuroscience
  • Genetics
  • Pediatric Critical Care

Background:

  • Traumatic brain injury (TBI) in children can lead to significant morbidity and mortality.
  • Cerebral perfusion pressure (CPP) is a critical indicator of brain oxygenation and outcome.
  • Apolipoprotein E (APO E) gene polymorphisms are associated with various neurological conditions.

Purpose of the Study:

  • To investigate the association between APO E alleles, CPP insult severity, and clinical outcomes in pediatric TBI patients.
  • To determine if APO E genotype influences the brain's tolerance to ischemic insults following TBI.

Main Methods:

  • Prospective case-control study involving 65 critically ill children with TBI.
  • Genotyping for APO E alleles and correlation with age-related CPP insult quantification.
  • Assessment of neurological status at intensive care discharge and 6-month global outcome.

Main Results:

  • Children with the APO E e4 allele and poor outcomes had significantly lower CPP insult levels compared to non-e4 carriers.
  • APO E e3 homozygotes with good recovery tolerated substantially higher CPP insults than non-e3 homozygotes.
  • These findings suggest a differential impact of APO E alleles on cerebral ischemic tolerance.

Conclusions:

  • APO E genotype may modulate the brain's response to ischemic injury in pediatric TBI.
  • Understanding the role of APO E alleles could inform targeted therapeutic strategies for TBI management in children.
  • Further research is warranted to elucidate the precise mechanisms underlying APO E's neuroprotective or detrimental effects in pediatric TBI.
Abstract